BR112018073676A2 - lipossomas peguilados e métodos de uso - Google Patents
lipossomas peguilados e métodos de usoInfo
- Publication number
- BR112018073676A2 BR112018073676A2 BR112018073676-7A BR112018073676A BR112018073676A2 BR 112018073676 A2 BR112018073676 A2 BR 112018073676A2 BR 112018073676 A BR112018073676 A BR 112018073676A BR 112018073676 A2 BR112018073676 A2 BR 112018073676A2
- Authority
- BR
- Brazil
- Prior art keywords
- pegylated
- pegylated liposomes
- methods
- liposomes
- lipid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/739—Lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662337328P | 2016-05-16 | 2016-05-16 | |
US62/337,328 | 2016-05-16 | ||
PCT/US2017/032756 WO2017200957A1 (en) | 2016-05-16 | 2017-05-15 | Pegylated liposomes and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018073676A2 true BR112018073676A2 (pt) | 2019-02-26 |
BR112018073676B1 BR112018073676B1 (pt) | 2023-10-03 |
Family
ID=58794159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018073676-7A BR112018073676B1 (pt) | 2016-05-16 | 2017-05-15 | Lipossomas peguilados e métodos de uso |
Country Status (12)
Country | Link |
---|---|
US (2) | US11266602B2 (pt) |
EP (1) | EP3458028A1 (pt) |
JP (2) | JP7195147B2 (pt) |
KR (1) | KR102483033B1 (pt) |
CN (1) | CN109562057A (pt) |
AU (2) | AU2017268175B2 (pt) |
BR (1) | BR112018073676B1 (pt) |
CA (1) | CA3023672A1 (pt) |
IL (1) | IL263030A (pt) |
MX (1) | MX2018013640A (pt) |
WO (1) | WO2017200957A1 (pt) |
ZA (1) | ZA201807128B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102483033B1 (ko) | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
CN107998070A (zh) * | 2017-12-12 | 2018-05-08 | 南京中医药大学 | 一种复合磷脂传递体及其在制备经皮给药制剂中的应用 |
EP3886901A1 (en) * | 2018-11-29 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Methods for manufacturing an adjuvant |
JP7487187B2 (ja) | 2018-12-17 | 2024-05-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソームを含む製剤 |
CN110151702A (zh) * | 2019-06-24 | 2019-08-23 | 昆明医科大学 | 聚乙二醇修饰流感疫苗脂质体及其制备方法 |
US11679163B2 (en) | 2019-09-20 | 2023-06-20 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
KR102328531B1 (ko) * | 2020-01-23 | 2021-11-17 | 서울대학교산학협력단 | 체내 면역 세포 표적 황화수소 공여체 담지 리포좀을 포함하는 면역질환 치료 또는 예방용 약학 조성물 |
AU2021241355A1 (en) | 2020-03-23 | 2022-10-13 | Hdt Bio Corp. | Compositions and methods for delivery of RNA |
WO2022136952A1 (en) | 2020-12-23 | 2022-06-30 | Infectious Disease Research Institute | Solanesol vaccine adjuvants and methods of preparing same |
WO2022183120A1 (en) * | 2021-02-26 | 2022-09-01 | University Of Virginia Patent Foundation | Development of covid-19 vaccine using a dual tlr ligand liposome adjuvant |
EP4304567A1 (en) * | 2021-03-11 | 2024-01-17 | The Trustees of the University of Pennsylvania | Targeted therapeutic lipid nanoparticles and methods of use |
CN115737800B (zh) * | 2023-01-09 | 2023-05-23 | 江苏瑞科生物技术股份有限公司 | 一种复合脂质体佐剂及其制备方法 |
Family Cites Families (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4286592A (en) | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4379454A (en) | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
FI861417A0 (fi) | 1985-04-15 | 1986-04-01 | Endotronics Inc | Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav. |
US4948587A (en) | 1986-07-08 | 1990-08-14 | Massachusetts Institute Of Technology | Ultrasound enhancement of transbuccal drug delivery |
US4767402A (en) | 1986-07-08 | 1988-08-30 | Massachusetts Institute Of Technology | Ultrasound enhancement of transdermal drug delivery |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
EP1088830A3 (en) | 1987-06-22 | 2004-04-07 | Medeva Holdings B.V. | Hepatitis b surface antigen particles |
US4780212A (en) | 1987-07-31 | 1988-10-25 | Massachusetts Institute Of Technology | Ultrasound enchancement of membrane permeability |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
GB2232892B (en) | 1988-02-23 | 1991-07-24 | John Mark Tucker | Occlusive body for administering a physiologically active substance |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8819209D0 (en) | 1988-08-12 | 1988-09-14 | Research Corp Ltd | Polypeptide & dna encoding same |
US4999403A (en) | 1988-10-28 | 1991-03-12 | Exxon Chemical Patents Inc. | Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions |
HUT58804A (en) | 1988-12-16 | 1992-03-30 | James Cleland Paton | Process for producing pneumolysine mutants and pneumococcus vaccines |
SG48175A1 (en) | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
US5256643A (en) | 1990-05-29 | 1993-10-26 | The Government Of The United States | Human cripto protein |
GB9106048D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccines |
DE122007000023I1 (de) | 1991-07-19 | 2007-08-09 | Univ Queensland St Lucia | Impfsstoff gegen Humanes Papillomavirus (typ 18) |
US5464387A (en) | 1991-07-24 | 1995-11-07 | Alza Corporation | Transdermal delivery device |
JP3954643B2 (ja) | 1991-11-16 | 2007-08-08 | グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム | マラリア原虫由来のCSおよびHBsAG間のハイブリッド蛋白質 |
DE122007000096I1 (de) | 1992-06-25 | 2008-03-27 | Papillomavirus vakzine | |
US5786148A (en) | 1996-11-05 | 1998-07-28 | Incyte Pharmaceuticals, Inc. | Polynucleotides encoding a novel prostate-specific kallikrein |
US5437951A (en) | 1992-09-03 | 1995-08-01 | The United States Of America As Represented By The Department Of Health And Human Services | Self-assembling recombinant papillomavirus capsid proteins |
DE122007000090I1 (de) | 1993-03-09 | 2008-03-27 | Univ Rochester | Herstellung von menschlichem papillomavirus hüllprotein und virus-ähnlichen teilchen |
KR100341341B1 (ko) | 1993-07-15 | 2002-11-25 | 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 | 이미다조[4,5-c]피리딘-4-아민 |
US6033928A (en) | 1993-11-02 | 2000-03-07 | Matsushita Electric Industrial Co., Ltd. | Method of manufacturing aggregate of semiconductor micro-needles |
US5885211A (en) | 1993-11-15 | 1999-03-23 | Spectrix, Inc. | Microporation of human skin for monitoring the concentration of an analyte |
US5458140A (en) | 1993-11-15 | 1995-10-17 | Non-Invasive Monitoring Company (Nimco) | Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers |
US5814599A (en) | 1995-08-04 | 1998-09-29 | Massachusetts Insitiute Of Technology | Transdermal delivery of encapsulated drugs |
US5688506A (en) | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
US5457041A (en) | 1994-03-25 | 1995-10-10 | Science Applications International Corporation | Needle array and method of introducing biological substances into living cells using the needle array |
US5591139A (en) | 1994-06-06 | 1997-01-07 | The Regents Of The University Of California | IC-processed microneedles |
ATE325875T1 (de) | 1994-10-07 | 2006-06-15 | Univ Loyola Chicago | Papillomavirusähnliche partikel, fusionsproteine sowie verfahren zu deren herstellung |
JP3958360B2 (ja) | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
US5981215A (en) | 1995-06-06 | 1999-11-09 | Human Genome Sciences, Inc. | Human criptin growth factor |
US5618275A (en) | 1995-10-27 | 1997-04-08 | Sonex International Corporation | Ultrasonic method and apparatus for cosmetic and dermatological applications |
US5656016A (en) | 1996-03-18 | 1997-08-12 | Abbott Laboratories | Sonophoretic drug delivery system |
US5955306A (en) | 1996-09-17 | 1999-09-21 | Millenium Pharmaceuticals, Inc. | Genes encoding proteins that interact with the tub protein |
US7033598B2 (en) | 1996-11-19 | 2006-04-25 | Intrabrain International N.V. | Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal |
US5840871A (en) | 1997-01-29 | 1998-11-24 | Incyte Pharmaceuticals, Inc. | Prostate-associated kallikrein |
IL131539A0 (en) | 1997-02-25 | 2001-01-28 | Corixa Corp | Compounds for immunodiagnosis of prostate cancer and methods for their use |
CA2297374A1 (en) | 1997-07-21 | 1999-01-28 | North American Vaccine, Inc. | Modified immunogenic pneumolysin, compositions and their use as vaccines |
GB9717953D0 (en) | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
US7459524B1 (en) | 1997-10-02 | 2008-12-02 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, sequence and uses thereof |
EP2228385A1 (en) | 1997-11-28 | 2010-09-15 | Merck Serono Biodevelopment | Chlamydia trachomatis genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection |
UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
CA2584482C (en) | 1998-02-05 | 2012-03-27 | Smithkline Beecham Biologicals S.A. | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination |
NZ507378A (en) | 1998-04-07 | 2002-12-20 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis antigens and their uses |
GB2336310B (en) | 1998-04-14 | 2003-09-10 | Stowic Resources Ltd | Method of manufacturing transdermal patches |
JP2002511266A (ja) | 1998-04-15 | 2002-04-16 | ルードヴィッヒ インスティテュート フォー キャンサー リサーチ | 腫瘍関連核酸及びその使用 |
US6322532B1 (en) | 1998-06-24 | 2001-11-27 | 3M Innovative Properties Company | Sonophoresis method and apparatus |
HUP0203035A3 (en) | 1998-07-14 | 2007-12-28 | Corixa Corp | Compositions and methods for therapy and diagnosis of prostate cancer |
US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
DE60014076T2 (de) | 1999-04-19 | 2005-10-13 | Glaxosmithkline Biologicals S.A. | Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid |
US6685699B1 (en) | 1999-06-09 | 2004-02-03 | Spectrx, Inc. | Self-removing energy absorbing structure for thermal tissue ablation |
JP4162813B2 (ja) | 1999-10-28 | 2008-10-08 | 久光製薬株式会社 | イオントフォレーシス装置 |
US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
US6908453B2 (en) | 2002-01-15 | 2005-06-21 | 3M Innovative Properties Company | Microneedle devices and methods of manufacture |
US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
US7018345B2 (en) | 2002-12-06 | 2006-03-28 | Hisamitsu Pharmaceutical Co., Inc. | Iontophoresis system |
KR101494056B1 (ko) | 2003-10-03 | 2015-02-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | 피라졸로피리딘 및 그의 유사체 |
DE102005032175A1 (de) | 2005-07-09 | 2007-01-18 | Krones Ag | Behälter-Behandlungsmaschine und Verfahren zum Laden und Entladen einer Behälter-Behandlungsmaschine |
DE502005002538D1 (de) | 2005-07-19 | 2008-03-06 | Holzapfel Gmbh & Co Kg Geb | Auftriebshilfe |
US9333250B2 (en) * | 2006-04-06 | 2016-05-10 | The Johns Hopkins University | Methods and compositions for treating bacterial infection |
ES2673046T3 (es) * | 2006-09-26 | 2018-06-19 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
PL2510946T3 (pl) * | 2007-02-07 | 2015-12-31 | Univ California | Koniugaty syntetycznych agonistów tlr i ich zastosowania |
MX2009010800A (es) | 2007-04-04 | 2010-01-29 | Infectious Disease Res Inst Id | Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos. |
US8793881B2 (en) | 2008-08-15 | 2014-08-05 | Stanley Black & Decker, Inc. | Utility knife with blade lock |
KR20110050531A (ko) * | 2008-08-28 | 2011-05-13 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 백신 |
WO2010094663A1 (en) * | 2009-02-17 | 2010-08-26 | Glaxosmithkline Biologicals S.A. | Inactivated dengue virus vaccine with aluminium-free adjuvant |
CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
WO2010143971A2 (en) * | 2009-06-08 | 2010-12-16 | Epitarget As | Lipophilic drug carrier |
TWI397428B (zh) * | 2009-12-29 | 2013-06-01 | Ind Tech Res Inst | 標的第四介白素受體之傳輸系統 |
ES2943385T3 (es) * | 2010-08-17 | 2023-06-12 | 3M Innovative Properties Company | Compuesto modificador de la respuesta inmunitaria lipidada y su uso médico |
AU2011295935B2 (en) * | 2010-08-31 | 2016-02-11 | Glaxosmithkline Biologicals S.A. | Pegylated liposomes for delivery of immunogen-encoding RNA |
JP6240077B2 (ja) * | 2011-10-06 | 2017-11-29 | イムノバクシーン・テクノロジーズ・インコーポレイテッドImmunovaccine Technologies Inc. | Tlr2を活性化するか、またはその活性を増加させるアジュバントを含むリポソーム組成物およびその使用 |
US9370489B2 (en) | 2011-10-31 | 2016-06-21 | Mallinckrodt Llc | Combinational liposome compositions for cancer therapy |
WO2013086526A1 (en) * | 2011-12-09 | 2013-06-13 | The Regents Of The University Of California | Liposomal drug encapsulation |
PT2811981T (pt) * | 2012-02-07 | 2019-06-12 | Infectious Disease Res Inst | Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização |
EP3939572B1 (en) | 2012-04-12 | 2024-03-27 | Yale University | Vehicles for controlled delivery of different pharmaceutical agents |
WO2014008406A2 (en) * | 2012-07-05 | 2014-01-09 | Children's Medical Center Corporation | The bacterial biofilm matrix as a platform for protein delivery |
US10039716B2 (en) * | 2013-03-13 | 2018-08-07 | Mallinckrodt Llc | Liposomal cisplatin compositions for cancer therapy |
SG11201606625RA (en) | 2014-02-14 | 2016-09-29 | Immune Design Corp | Immunotherapy of cancer through combination of local and systemic immune stimulation |
BE1022346A9 (fr) * | 2014-03-12 | 2016-10-07 | Glaxosmithkline Biologicals Sa | Compositions liposomales pour une administration mucosale |
CN105534908B (zh) * | 2016-01-15 | 2018-12-14 | 徐州医学院 | 一种包载核酸药物的具缺氧响应能力和放疗增敏功能脂质体 |
KR102483033B1 (ko) | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
-
2017
- 2017-05-15 KR KR1020187034749A patent/KR102483033B1/ko active IP Right Grant
- 2017-05-15 US US16/098,619 patent/US11266602B2/en active Active
- 2017-05-15 JP JP2018559785A patent/JP7195147B2/ja active Active
- 2017-05-15 MX MX2018013640A patent/MX2018013640A/es unknown
- 2017-05-15 CN CN201780030294.4A patent/CN109562057A/zh active Pending
- 2017-05-15 WO PCT/US2017/032756 patent/WO2017200957A1/en unknown
- 2017-05-15 BR BR112018073676-7A patent/BR112018073676B1/pt active IP Right Grant
- 2017-05-15 CA CA3023672A patent/CA3023672A1/en active Pending
- 2017-05-15 EP EP17726411.6A patent/EP3458028A1/en not_active Withdrawn
- 2017-05-15 AU AU2017268175A patent/AU2017268175B2/en active Active
-
2018
- 2018-10-25 ZA ZA2018/07128A patent/ZA201807128B/en unknown
- 2018-11-15 IL IL263030A patent/IL263030A/en unknown
-
2021
- 2021-12-23 US US17/560,594 patent/US20220160632A1/en active Pending
-
2022
- 2022-09-09 JP JP2022143788A patent/JP2022177112A/ja active Pending
-
2023
- 2023-02-01 AU AU2023200515A patent/AU2023200515B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20220160632A1 (en) | 2022-05-26 |
KR20190025822A (ko) | 2019-03-12 |
MX2018013640A (es) | 2019-08-01 |
US11266602B2 (en) | 2022-03-08 |
IL263030A (en) | 2018-12-31 |
BR112018073676B1 (pt) | 2023-10-03 |
AU2023200515B2 (en) | 2024-04-18 |
WO2017200957A1 (en) | 2017-11-23 |
JP7195147B2 (ja) | 2022-12-23 |
JP2022177112A (ja) | 2022-11-30 |
ZA201807128B (en) | 2019-06-26 |
US20200138715A1 (en) | 2020-05-07 |
RU2018137866A (ru) | 2020-06-17 |
RU2018137866A3 (pt) | 2021-02-04 |
CA3023672A1 (en) | 2017-11-23 |
AU2017268175A1 (en) | 2018-11-15 |
AU2023200515A1 (en) | 2023-03-02 |
AU2017268175B2 (en) | 2023-02-23 |
JP2019518739A (ja) | 2019-07-04 |
EP3458028A1 (en) | 2019-03-27 |
CN109562057A (zh) | 2019-04-02 |
KR102483033B1 (ko) | 2022-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018073676A2 (pt) | lipossomas peguilados e métodos de uso | |
CR20220108A (es) | Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos | |
BR112017017949A2 (pt) | regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna | |
BR112018012794A2 (pt) | receptor de célula t, tcr que se liga a um complexo hla-a*02 sllmwitqc, fusão anti-cd3 de tcr, ácido nucléico, vetor de expressão, célula que ocorre e/ou purificada e/ou concebida de maneira não natural, célula, composição farmacêutica, método de tratamento de um indivíduo humano, formulação injetável para administração a um indivíduo humano, e método de produção de uma tcr | |
BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
BR112015027291A8 (pt) | uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor | |
BR112017008042A2 (pt) | métodos e composições para dosagem em terapia de célula adotiva | |
BR112014016810A8 (pt) | composições e métodos para tratamento de distúrbios metabólicos | |
BR112015011403A2 (pt) | uso de akkermansia para o tratamento de distúrbios metabólicos | |
BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
BR112014028633A8 (pt) | tratamento de amd usando sflt-1 de aav | |
BR112016006122A2 (pt) | composições imunogênicas e métodos com coronavírus da síndrome respiratória do oriente médio (mers-cov) | |
BR112015025025A2 (pt) | composições terapêuticas e usos das mesmas | |
BR112014024672A8 (pt) | Composições farmacêuticas para terapia de combinação | |
BR112014017920A8 (pt) | Preparação cosmética e/ou dermatológica à base de uma emulsão de água em óleo e uso da combinação de dois emulsificantes de água/óleo | |
BR112018075785A2 (pt) | formulação de vacina para o hiv | |
BR112017026287A2 (pt) | composições de hidroxipropil beta-ciclodextrina e métodos | |
BR112016025764A2 (pt) | vacina de peptídeo compreendendo peptídeo ras mutante e agente quimioterapêutico | |
BR112015017246A8 (pt) | composição farmacêutica aquosa, seu uso e seringa | |
BR112012028893A2 (pt) | composições imunoestimuladoras e de vacina | |
BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
BR112018017031A2 (pt) | formulações de antagonista de il-6 e usos das mesmas | |
BR112015022415A2 (pt) | composições de cisplatina lipossômica para terapia contra câncer | |
CO2018012506A2 (es) | Composiciones farmacéuticas y regímenes de dosificación para el uso clínico de anticuerpos contra el antígeno 2 de las células dendríticas de la sangre | |
AR099960A1 (es) | Procedimientos y composición farmaceutica para inducir una respuesta inmunitaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: INFECTIOUS DISEASE RESEARCH INSTITUTE (US) ; UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870230026041, DE 28/03/2023, E NECESSARIO APRESENTAR DOCUMENTO NOTARIZADO. ALEM DISSO, E PRECISO APRESENTAR A GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: INFECTIOUS DISEASE RESEARCH INSTITUTE (US) ; UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) Free format text: ANULADA A PUBLICACAO CODIGO 25.6 NA RPI NO 2740 DE 11/07/2023 POR TER SIDO INDEVIDA. |
|
B25D | Requested change of name of applicant approved |
Owner name: UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) ; ACESS TO ADVANCED HEALTH INSTITUTE (US) |
|
B25K | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication |
Owner name: UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) ; ACCESS TO ADVANCED HEALTH INSTITUTE (US) Free format text: RETIFICACAO DO DESPACHO (25.4) ? ALTERACAO DE NOME PUBLICADO NA RPI NO 2744, DE 08/08/2023, QUANTO AO ITEM (71) - DEPOSITANTE.ONDE SE LE: ACESS TO ADVANCED HEALTH INSTITUTE LEIA-SE: ACCESS TO ADVANCED HEALTH INSTITUTE |
|
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/05/2017, OBSERVADAS AS CONDICOES LEGAIS |